Purpose: Isoform-specific tumor estrogen receptor b (ERb) expression may hold prognostic information in breast cancer, especially among endocrine-treated breast cancer patients. The study's purpose was to evaluate ERb isoform 1 (ERb1) expression in relation to tumor characteristics, ESR2 genotypes, and prognosis in different treatment groups.
Introduction
The complexity of estrogen receptor (ER) signaling in breast cancer was further revealed with the discovery of ERb in the 1990s (1) . ERb is encoded by estrogen receptor gene 2 (ESR2), which is highly polymorphic. The majority of the genetic variation can be captured by four haplotype tagging single SNPs (htSNP; ref. 2) . We have previously reported that ESR2 genotypes seem to divide patients into good and poor survivors, depending on the body mass index (BMI) of the patient (3) . Whether ESR2 genotypes are associated with ERb tumor expression is currently unknown. ERb is a transcription factor that has been suggested to regulate ERa activity (4) and to have an antiproliferative and tumor-suppressing role (5) . ERb may also have different effects depending on the currently known five different isoform variants expressed at the protein level (6) . Highly specific antibodies have been called for, to better characterize the role of ERb and its variants in breast cancer, with the ultimate aim to develop specific ERb agonists to improve breast cancer treatment (7) .
In terms of outcomes, tumor ERb expression (total and isoform specific) has been positively associated with favorable prognosis, especially when ERb was coexpressed with ERa, but also for patients with ERa À /ERb þ tumors (8) . Contrasting findings of ERb-driven proliferative effects, foremost in ERa À tumors, have suggested a differential role for ERb, depending on breast cancer subtype (9, 10) . As the results from clinical studies have been inconsistent, large prospective trials that examine isoform-specific ERb expression stratified by ERa status have been called for (5) . Recently, the first meta-analysis on clinical outcomes in relation to ERb expression in nonmetastatic breast cancer was published. The ERb isoforms 1, 2, and 5 (ERb1, ERb2/cx, and ERb5) were assessed at either the protein or mRNA level (11) ; the main finding was that tumor ERb1 expression was favorable for disease-free survival (DFS) irrespective of ERa status and was also favorable for overall survival (OS) among patients with ERa þ tumors. ERb2 was only prognostic for DFS, while ERb5 was not associated with the outcome. The authors proposed that this prognostic significance of ERb would suggest new molecular subtypes of hormonesensitive breast cancer. However, the potential treatment-predictive value of ERb was not analyzed in the meta-analysis, and the heterogeneity of these retrospective study populations in terms of age and subtypes was pointed out (11) .
The beneficial impact of ERb expression on endocrine treatment response has been repeatedly reported (8, (12) (13) (14) . Recently, the first results from the Intergroup Exemestane Study highlighted the potential importance of ERb expression in relation to endocrine treatment response, and also its complexity. Therein, ERb1 was not prognostic among all endocrine-treated patients. However, the patients with ERa þ breast tumors with low, but not with high, ERb1 expression had a survival benefit from the switch from tamoxifen to exemestane (15) .
Furthermore, Wang and colleagues showed that high tumor ERb1 expression was an independent prognostic marker for DFS and OS in a large retrospective series of triple-negative breast cancer (TNBC) patients and proposed specific ERb agonists as a potential addition to chemotherapy for these patients (16) . The ERb agonist S-equol is currently being evaluated in a presurgical setting for TNBC patients in a phase 0 clinical trial (ClinicalTrials. gov identifier: NCT0235202).
We hypothesized that ERb1 expression is prognostic in primary breast cancer irrespective of ERa status and that it can impact clinical outcomes, especially among endocrine-treated patients.
The aim of this study was to elucidate whether tumor ERb1 expression was associated with established clinicopathologic markers and risk of breast cancer events, both for the overall study population and in different adjuvant treatment groups, in a population-based prospective cohort of primary breast cancer. A secondary aim was to assess whether tumor ERb1 expression was associated with the previously studied ESR2 genotypes in this cohort.
Materials and Methods
The study cohort
The BC Blood Study is an ongoing population-based prospective cohort study at the Ska ne University Hospital (Lund, Sweden). It explores the impact of genetic and lifestyle factors on prognosis and treatment in primary breast cancer. Patients diagnosed with primary breast cancer are invited to participate at their preoperative visit. Exclusion criteria are a history of cancer in the last 10 years or any history of breast cancer (17) .
This study included patients from October 2002 to June 2012 (N ¼ 1,116). After excluding patients with in situ only cancers or who had received preoperative treatment, the final study cohort consisted of 1,026 patients ( Fig. 1 ). Preoperatively, patients filled out questionnaires on lifestyle and medication use. Body measurements were taken and blood samples were collected by a research nurse. For patients with no previous breast surgeries, breast size was measured using plastic cups (18) . Clinical information and patient characteristics were retrieved through medical records and combined with information from follow-up questionnaires at 3 to 6 months, as well as 1, 2, 3, 5, 7, 9, and 11 years postoperatively, thus providing information regarding adherence (19) .
Patients were followed until June 30, 2014. Information on survival and breast cancer events was retrieved from the Swedish National Register on Causes of Death, the Regional Tumor Registry, pathology reports, and patient charts. Local or regional recurrences, contralateral cancers, or distant metastasis were considered as endpoints in DFS analyses. For analyses of distant metastasis-free survival (DMFS) and OS, distant metastasis and death from any cause, respectively, were used as endpoints. Patients were censored at the time of a non-breast cancer-related death or last follow-up.
Genotyping of the ESR2 htSNPs (rs4986938, rs1256031, rs1256049, and rs3020450) was performed, and haplotypes were constructed as described previously (3) .
All patients signed informed consents upon enrolment. The study was approved by the Lund University Ethics Committee (Dnr LU75-02, LU37-08, LU658-09, LU58-12, LU379-12, LU227-13, LU277-15, and LU458-15).
Histopathological analyses
Tumor specimens were retrieved as formalin-fixed paraffinembedded blocks from which tissue microarrays (TMA) with duplicate 1-mm cores were constructed, as described previously (20) . Four-micrometer TMA sections were cut for immunohistochemical semiautomated staining of ERb1 (Autostainer Plus, Dako), using the ERb1-specific mAb clone PPG5/10 (M7292, Dako, dilution 1:20). Semiquantitative scoring of ERb1 was performed twice independently by one researcher (K. Elebro) blinded to the clinical outcome. In cases where discrepancies occurred, a third scoring was performed (K. Elebro þ A.H. Rosendahl) to reach consensus. Fractions were assessed as 0%, 1%-10%, 11%-20%, 21%-75%, 76%-100 % of positively stained nuclei, and intensity as none, weak, moderate, or strong nuclear staining intensity, irrespective of cytoplasmic staining. Two cut-off points for positivity were evaluated: >75% and >10% of positively stained nuclei. If the duplicate cores were discordant, the fraction of positively stained nuclei was estimated across both sampled cores.
Information on the clinically established tumor markers, such as ERa and progesterone receptor (PR) expression (cutoff at >10% positively stained nuclei), was collected from pathology reports, as described previously (20) (21) (22) . HER2 status (amplified/nonamplified) was available for 688 (93.2%) patients as of November 2005, when HER2 assessment was introduced into Swedish clinical routines for patients younger than 70 years of age. Information on histological type and grade, invasive tumor size, and axillary lymph node involvement (ALNI) was retrieved from the patient charts and pathology reports. The TMAs had been previously assessed for androgen receptor (AR) expression (20) .
Translational Relevance
In this large, prospective population-based cohort of primary breast cancer, high tumor expression of estrogen receptor b (ERb1; >75%) was associated with favorable clinicopathologic characteristics, but not with the previously studied germline ESR2 genotypes. In chemotherapy-treated patients, high ERb1 was an independent favorable prognostic marker. In contrast, high ERb1 expression was not associated with better outcomes in endocrine-treated patients, as has been previously reported by other groups. The results warrant confirmation, preferably via a biomarker study in an already performed randomized controlled trial, to enable evaluation of chemotherapy response in relation to high ERb1 expression.
Statistical analyses
The statistical analyses were conducted with the software program SPSS version 22.0 (IBM). Descriptive patient and tumor characteristics were summarized as either continuous variables (median, interquartile range) or categorical (number, percentage) variables, in relation to ERb1 status (AE, or missing ERb1 status). The potential associations between these variables and ERb1 status (AE) were analyzed by the Mann-Whitney U test, or by c 2 or logistic regression analyses, for which ORs with 95% confidence intervals (CI) are presented. To examine whether there was an effect modification by ERa on the association between AR and ERb1 expression, a multiplicative interaction variable between AR and ERa was calculated and included in the logistic regression model. Categories were based on either previously studied cutoffs [i.e., BMI (!25 kg/m 2 ), total breast size !850 mL (18)] or dichotomized variables (parous, ever use of oral con-traceptive, ever use of hormone therapy, coffee intake !2 cups/ day, current smoking prior to surgery, and alcohol abstainer). Tumor characteristics were categorized as follows: tumor size (invasive 20 mm, 21-50 mm, !51 mm, or skin or muscle involvement independent of size), ALNI (0, 1-3, 4þ), histologic grade (1, 2, 3), ERa, PR, AR, combinations of ERa and PR status, and HER2 status (amplified/nonamplified). Information on adjuvant treatment by last follow-up and before any event was dichotomized for chemotherapy, radiotherapy, tamoxifen, and aromatase inhibitors (AI). Trastuzumab treatment was incorporated into subgroup analyses of treatments for the patients included as of November 2005.
The impact of ERb1 expression on DFS was assessed by Kaplan-Meier curves and the log-rank test. Analyses were performed for ERb1 status alone and in combination with ERa status. Stratification by various treatment groups was performed; regarding endocrine treatment, analyses were performed within the ERa þ group, with and without chemotherapy, and stratified by type of endocrine treatment and age (</!50 years). The prognostic importance of ERb1 alone, or in combination with ERa, was further analyzed by univariable and multivariable Cox regression analyses, yielding HRs with 95% CIs. Adjustments were performed in four models: Model 1: age (continuous) and tumor characteristics (invasive tumor size >20 mm or skin or muscular involvement irrespective of size, grade 3, any ALNI, ERa status); model 2: age, tumor characteristics, BMI, and smoking; model 3: age, tumor characteristics, and treatment (chemotherapy, radiotherapy, tamoxifen, AI); model 4: model 3 with the addition of trastuzumab treatment and restricted to patients included as of November 2005. Patients with tumors without available ERb1 status (n ¼ 115) and patients who were diagnosed with distant metastasis within 0.3 years or closer to inclusion (n ¼ 8) were excluded from survival analyses ( Fig. 1 ).
Prior power calculations assuming 900 patients with an accrual interval of 10 years and additional follow-up time of 0.5 years showed that the study was able to detect true HRs between 0.66 and 1.62 if the frequency of ERb1 À tumors was 10% (and 0.75-1.37 if 25% ERb1 À ), with 80% power and a of 5% (power and sample size calculation program, PS, version 3.0, developed by Dupont and Plummer; http://biostat.mc.vanderbilt.edu/wiki/ Main/PowerSampleSize). Nominal P values without correction for multiple testing are presented. All statistical tests were twosided, and P values less than 0.05 were considered significant. This report adheres to the REMARK criteria (23) .
Results

Patient and tumor characteristics by ERb1 status
Valid tumor ERb1 scores were obtained from 911 patients (88.8%). Using the cutoff >75% of positively stained nuclei, 662 patients (72.7%) displayed ERb1 75 positive (ERb1 75 þ ) tumors. These patients were older at inclusion and had smaller breast volumes compared with patients with ERb1 75 negative (ERb1 75 À ) tumors. Other patient characteristics, such as anthropometric measures, reproductive factors, and ever use of exogenous hormones, showed no significant associations with ERb1 75 status ( Table 1 ). In terms of tumor characteristics, ERb1 75 þ was associated with smaller tumor size, lower histologic grade, less axillary lymph node involvement, as well as coexpression of ERa, PR, and AR ( Table 2 ). Tumors that coexpressed ERa and AR were six times more likely to also express ERb1 75 þ compared with no expression or expression of one but not both of the other receptors (OR ¼ 6.41; 95% CI, 2.54-16.14; P interaction < 0.0001). In the subgroup where HER2 status was available, HER2 amplification was more common in ERb1 75 À tumors compared with ERb1 75 þ tumors. The lowest frequency of HER2 amplification was found in tumors that coexpressed ERa and ERb1 75 (7.8%). HER2 amplification was most common in ERa À tumors, irrespective of ERb1 75 and/or PR status (30.3%-32.3%; Table 2 ). ERb1 positivity, defined as >10% of positively stained nuclei [ERb1 10 þ , n ¼ 839 (92.1%)], was associated with ERa and AR coexpression (Ps < 0.0001). ERb1 10 þ did not demonstrate significant associations with other tumor markers, such as invasive tumor size, histologic grade, ALNI, PR expression, and HER2 amplification. Furthermore, it was not significantly associated with any patient-related factors, such as anthropometric measures, reproductive factors, or exogenous hormone use. Tumor ERb1 75 and ERb1 10 expression was not significantly associated with the four germline ERb htSNPs or the two haplotypes "any TCAC" or the number of CCGC, either overall or in patients with BMI !25 kg/m 2 , where two htSNPs and the two haplotypes were differently associated with DFS depending on BMI in our previous report (3) .
DFS by ERb1 status
Patients were followed for up to 11 years (median follow-up 5.0 years for patients still at risk). In the overall study population, patients with ERb1 75 þ tumors had approximately two thirds the risk for any breast cancer event compared with patients with . This association remained significant after adjusting for age, tumor characteristics, and adjuvant treatment (Fig. 3A) . The association remained significant in the ERa À subgroup (log-rank P ¼ 0.024; HR adj ¼ 0.12; 95% CI, 0.03-0.51) and in the ERa þ subgroup (log-rank P ¼ 0.024; HR adj Bold letters indicate statistically significant results. HRs are presented with 95% confidence intervals (CI) and are adjusted for a ERa status (AE), b invasive tumor size (<21 mm vs. !21 mm, or skin or muscular involvement independent of size), axillary lymph node involvement (yes/no), tumor grade 3 (yes/no), age (continuous), and adjuvant treatment ( c radiotherapy yes/no, chemotherapy yes/no, tamoxifen yes/no, AIs yes/no, d radiotherapy yes/no, chemotherapy yes/no). ¼ 0.35; 95% CI, 0.14-0.86). ERa status had no impact on prognosis within the chemotherapy-treated group (Fig. 3B ). Among the 671 chemona€ ve patients, there was no significant association between ERb1 75 status and DFS ( Fig. 3C and D) . Conversely, ERa was significantly associated with risk for breast cancer events among chemona€ ve patients, but not among chemotherapy-treated patients ( Fig. 3B and D) .
In terms of endocrine treatment, ERb1 75 þ was not associated with risk of any breast cancer event among the patients with ERa þ tumors who received tamoxifen and/or AIs (both logrank Ps ! 0.25). Among the tamoxifen-treated patients with ERa þ tumors who had also received chemotherapy, a tendency toward better prognosis with ERb1 75 þ was seen in patients <50 
Discussion
In this study, high tumor ERb1 expression was associated with favorable clinicopathological characteristics, but not with the previously studied ESR2 genotypes. High tumor ERb1 expression was identified as an independent favorable prognostic marker in breast cancer, especially for patients who received adjuvant chemotherapy. Previous reports of ERb1 as a predictor of endocrine therapy response could not be confirmed in this cohort.
ERb has high expression in normal breast tissue, and loss of ERb expression is considered an early event in breast cancer progression (24). One possible mechanism for ERb downregulation is promotor methylation, leading to loss of ERb expression and thus reduced antiproliferative effects (5) . Our group previously reported that the association between BMI and prognosis was dependent on ESR2 genotypes and that the key to understanding these results may be ERb promotor methylation, which may explain the previously reported association between ESR2 Figure 3 . A-D, DFS by ERb1 75 status, alone and in combination with ERa, among patients who received adjuvant chemotherapy (A and B, respectively; n ¼ 232), and chemona€ ve patients (C and D, respectively, n ¼ 671). Because this is an ongoing cohort, the number of patients decreased with each follow-up. Bold letters indicate statistically significant results. HRs are presented with 95% CI and adjusted for a ERa status (AE), b invasive tumor size (<21 mm vs. !21 mm, or skin or muscular involvement independent of size), axillary lymph node involvement (yes/no), tumor grade 3 (yes/no), age (continuous); and adjuvant treatment ( c radiotherapy yes/no, tamoxifen yes/no, AIs yes/no).
genotypes and anthropometrics (3) . However, in the current study, there was no association between the previously studied ESR2 genotypes and tumor-specific ERb1 expression, irrespective of the cutoff used. It is possible that the germline ESR2 genotypes affect ERb expression or signaling on a systemic level that is not reflected in the tumor-specific ERb expression. In addition, ERb1 expression and anthropometrics were not associated. Further studies are needed to understand how germline genotypes might be associated with the tumor expression of the corresponding protein.
We could confirm our hypothesis that patients with high tumor ERb1 expression had a better prognosis compared with patients with low ERb1 expression. The association remained significant in analyses adjusted for ERa expression. The magnitude of the association was larger within the ERa À population. This may be explained by the shift of ERb transcriptional binding sites that occurs in the absence of ERa (25) and was recently discussed in a review and meta-analysis (26) . Another tentative mechanistic explanation may be the more pronounced ligand-independent actions and basal activity of ERb compared with that of ERa (27) . Previous results from this cohort suggested that the prognostic role of AR in breast cancer was dependent on the ERa status of the tumor (20) . Similar hypotheses have been proposed for ERb (10) , and an in vitro study suggested ERb to be the link between AR and ERa interactions (28) . However, in the current study, unlike AR, ERb1 75 þ was prognostically beneficial irrespective of ERa expression. In line with this finding, the association between ERb and AR was dependent on ERa status, and the interaction was significant. To our knowledge, this has not been reported previously and merits further studies. If verified, these divergent prognostic results for AR and ERb in patients with ERa À tumors would suggest opposite targeted treatment strategies for each: antiandrogens as a treatment option in the ERa À /AR þ setting, whereas patients with ERa À /ERb1 75 þ would rather benefit from ERb agonists. However, a triple signature (6) was not explored in this study. In a study by Honma and colleagues, patient outcome was analyzed by several ERb antibodies, and the authors suggested that ERb1 should be added to ERa and PR assessment in clinical routine (14) . Therein, all patients received tamoxifen, also some patients with ERa-tumors, and ERb1 was a prognostic marker irrespective of ERa status, which is in line with our findings. A recent meta-analysis also supports this finding (11) . Furthermore, patients with ERa À /ERb1 75 þ tumors seemed to have good prognosis, on a level comparable with the prognosis for patients with ERa þ /ERb1 75 þ tumors. We concluded that patients with doublenegative (ERa À /ERb1 75 À ) tumors had inferior prognosis in all adjusted models and thus remain a prognostically vulnerable group, with few targeted treatment options, for whom closer surveillance may be indicated.
The subgroup of patients with ERa À /ERb1 75 þ breast cancer would be a likely candidate patient population to target with ERb agonists, as tested in an ongoing clinical trial (ClinicalTrials.gov identifier: NCT02352025). In addition, a recent phase II trial indicated that estradiol treatment might be beneficial in a selected ERb þ TNBC population (29) . One in vitro study reported that ERb agonists reduced cell invasion and the metastatic potential of TNBC (30) . Also, new ways of directing ligands to nuclear hormone targets are under way (31) , which was recently suggested as a future possibility for ERb targeting (10) .
A number of clinical studies have showed ERb expression, either as pan-specific ERb or as different isoforms, to be related to good prognosis and response to endocrine treatment (9) (10) (11) . Contrasting results from large cohorts have also been reported; the Nurses' Health Study included 2,170 breast cancer patients with tumors of different molecular subtypes (32) : It reported no association between ERb1 expression and breast cancer-specific survival, either overall or within the tamoxifen-treated group (32) . In the randomized controlled MA12-trial, tamoxifen-treated patients with ERb1 þ tumors and who previously received chemotherapy had better survival than patients with ERb1 À tumors, especially if the tumor was ERa À /ERb1 þ (33) . In the cohort presented by Nakopoulou and colleagues, in which patients received adjuvant chemotherapy and/or endocrine therapy, results were similar to our findings (34) . As many of the clinical studies were observational studies and patients often received both chemotherapy and endocrine therapy (35, 36) , it is somewhat surprising that associations between ERb and chemotherapy have been rarely discussed (7, 24) .
The main finding in this study was the impact of ERb1 75 expression on prognosis among patients who received adjuvant chemotherapy, some of whom also received tamoxifen and/or AIs. Thus, we performed stratified analyses according to age, chemotherapy, and type of endocrine treatment for all three endpoints in patients with ERa þ tumors. However, we could not confirm our hypothesis that ERb1 has an endocrine responsepredictive role. The minor finding on tamoxifen response in relation to DFS in one single subgroup appeared to be driven by chemotherapy. For DMFS, the prognostic findings were similar to the findings for DFS. In analysis of OS, ERb1 75 expression was an independent prognostic marker, foremost in ERa À disease. In OS analyses by treatment groups, an association between ERb1 75 expression and response to tamoxifen but not to AIs was observed in the subgroup of chemona€ ve patients !50 years. Our interpretation of this finding was that these patients more often die from other causes than their breast cancer, rather than reflecting improved response to tamoxifen treatment. Thus, in this cohort, the additional assessment of ERb1 did not seem to improve the prediction of endocrine response to either AIs or tamoxifen, which suggests a role for ERb1 in hormone-independent settings. We could not assess endocrine response among patients with ERa À / ERb þ tumors, which has previously been described (12) .
The strength of the study was that it was a prospective, population-based study with a wide variety of baseline and follow-up information and with high follow-up (37) . As with all observational studies, the current study has built-in limitations, such as changes in treatment regimens over time and differences in the selection of treatment and how they are combined. This may account for the null finding on endocrine treatment and also limits the possibilities of comparing our result with previous randomized controlled trials, such as the study by Speirs and colleagues (15) . Although Speirs and colleagues reported ERb1 to be prognostic among patients who received switch treatment, they did not detect a prognostic benefit of ERb1 expression in their overall population, in which all women received endocrine treatment. This is in line with our findings. The follow-up period was relatively short, especially given that ERa þ tumors tend to relapse late, which may be one reason why any findings may have been more pronounced in patients with ERa À tumors. There was no question on ethnicity in the questionnaire for this study, but the majority of the study participants were of Swedish origin. The main reason for nonparticipation was the lack of available research nurses (17) . The age and frequency of ERa þ in the cohort is similar to that of the Southern Sweden breast cancer population (18) , indicating that the cohort is representative. Furthermore, the tumor analyses were based on TMAs, and even though some tumor cores were missing, we found no indication of bias. In the current study, assessment of Ki67 was not incorporated as Ki67 was not introduced into Swedish clinical routine until March 2009; however, it would be of interest to assess in future studies.
Our results regarding chemotherapy were in accordance with the recent study by Wang and colleagues, in which high ERb1 tumor expression was an independent prognostic marker for chemotherapy-treated patients with TNBC tumors without endocrine treatment or trastuzumab (16) . The finding was also supported by a neoadjuvant study, in which high pretreatment ERb expression was associated with lower proliferation rates and better pathologic response in the posttreatment samples (38) . An in vitro study suggested that the association might be explained by a chemosensitizing effect of ERb in tumor protein p53 (p53)mutant TNBC cell lines (39) . Contrasting results were reported by a study on ERa þ breast cancer cell lines where ERb expression was associated with chemotherapy resistance, whereas tamoxifen response was independent of ERb expression (40) . Another study reported a chemosensitizing effect of ERb5 expression, irrespective of the ERa and p53 status of the cell line (41) . In the current study, p53 status was not available for analysis, and the response to chemotherapy was observed irrespective of ERa expression.
Some of the discrepancies between the results from the clinical and functional ERb studies have been related to the different ERb isoforms, as well as interlaboratory differences (5, 42) . Also, there has been a lack of cancer cell models with reliable ERb expression (8) . A recent review that addressed clinical outcome in relation to ERb expression focused exclusively on studies that used the validated antibodies ppg5/10 (42-44) and 57/3, directed at ERb1 and ERb2, respectively (7) . ERb1, the wild-type isoform, has ligand-binding ability and has been described as the only fully functional isoform (45) . We therefore chose to address the prognostic effect of ERb using the ppg5/10 ERb1-specific antibody that does not recognize and stain for ERa or ERb2.
The immunohistochemical analysis of tumor ERb1 expression has been far from standardized and merits further attention. The cutoffs used to define positivity have been described in many ways, including not defined, as "distinct nuclear staining" (32) , or more commonly defined as >10% of positively stained nuclei (14, 34, 35) . Also, scoring systems based on combinations of fraction and intensity have been commonly applied (16, 33, (46) (47) (48) . Higher cutoffs, such as >20% (12, 46, 49, 50) or higher (33, 34, 36) , have also been applied. One highly cited study applied cutoffs for ERb1 þ that resulted in highly skewed distributions; >95% of the patients had ERb1 þ tumors, and although there was a tendency toward a beneficial effect, it was reported as a null finding (46) . A dose-response effect has been observed, either by grouped fractions (34) or by groups of stronger staining intensity (12) . ERb positivity has also been defined by moderate or stronger intensity, thereby excluding the weakly stained cases (12, 36, 49) . Some previous studies have applied cutoffs that ultimately suggested significant prognostic effects on outcome, yet which displayed few, if any, associations with established clinicopathologic characteristics (12, 34, 36, 49) , whereas others reported only associations between ERb1 þ and established markers (32) .
In the current study, we tried to address the above-mentioned issues by choosing a cutoff for which we could observe both associations with established clinicopathological characteristics and prognostic impact, as has been done previously (14, 16, 48) . The recent meta-analysis reported ERb1 þ of 67% across studies, in spite of varying cut-off point definitions (11) , and we reported ERb1 75 þ of 73%. We chose to also report the null findings for the cutoff >10%, as that cutoff has also been commonly used. Finally, we decided not to include intensity in our score to reduce variability.
In conclusion, this study provides support for high tumor ERb1 expression as a marker of good prognosis in breast cancer, especially among chemotherapy-treated patients, but not in endocrine therapy-treated patients. The results warrant confirmation, preferably in an already performed randomized controlled trial, to evaluate chemotherapy response in relation to high ERb1 expression.
